Akash Tewari
Stock Analyst at Jefferies
(2.44)
# 2,382
Out of 5,127 analysts
61
Total ratings
39.13%
Success rate
4.44%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $37.77 | -7.33% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $81.54 | +17.73% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $801.01 | +3.74% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $10.97 | +137.01% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $12.18 | -17.90% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $55.90 | +21.65% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $60.35 | +57.42% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $98.85 | +51.75% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $8.00 | +100.00% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $135.57 | +39.41% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $26.26 | +204.65% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,085.19 | -6.47% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $29.60 | +68.92% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $77.48 | -3.20% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $30.14 | +2.85% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $25.29 | +54.21% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.44 | +33.93% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $795.57 | -35.52% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $110.99 | +12.62% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $23.10 | -52.38% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.93 | +780.83% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $63.32 | +18.45% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $556.22 | -72.85% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $44.15 | -36.58% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $37.77
Upside: -7.33%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $81.54
Upside: +17.73%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $801.01
Upside: +3.74%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $10.97
Upside: +137.01%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $12.18
Upside: -17.90%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $55.90
Upside: +21.65%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $60.35
Upside: +57.42%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $98.85
Upside: +51.75%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $8.00
Upside: +100.00%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $135.57
Upside: +39.41%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $26.26
Upside: +204.65%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,085.19
Upside: -6.47%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.60
Upside: +68.92%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $77.48
Upside: -3.20%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $30.14
Upside: +2.85%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $25.29
Upside: +54.21%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.44
Upside: +33.93%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $795.57
Upside: -35.52%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $110.99
Upside: +12.62%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $23.10
Upside: -52.38%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.93
Upside: +780.83%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $63.32
Upside: +18.45%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $556.22
Upside: -72.85%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $44.15
Upside: -36.58%